Biomarker for predicting disease recurrence in non-metastatic papillary kidney cancer
A biomarker is a biological molecule found in blood, other [...]
Outcomes of patients who stopped immunotherapy due to immune-related side effects
Immunotherapy has changed the way advanced renal cell carcinoma (RCC) [...]
Atezolizumab plus bevacizumab does not improve survival in kidney cancer
Results from the IMmotion151 phase III clinical trial were published [...]
First-line nivolumab plus ipilimumab in kidney cancer patients without nephrectomy
A recent post hoc analysis of the CheckMate 214 trial [...]
Cabozantinib for the treatment of kidney cancer brain metastases
Brain metastases resulting from the spread of renal cell carcinoma [...]
Survival after nephrectomy for various kidney cancer subtypes
Data presented at the American Urological Association (AUA) 2021 meeting [...]
ESMO 2021: First-line nivolumab/ipilimumab – probability of survival in 5-year follow-up
The use of two medicines together (combination therapies) for previously [...]
Role of nephrectomy for metastatic kidney cancer in the immunotherapy era
Three phase III clinical trials (Keynote 426, Checkmate 9ER and [...]
Potential biomarker to predict risk of recurrence after nephrectomy for locally advanced kidney cancer
Currently, the search for a reliable biomarker to identify those [...]
Anti-cancer vaccine ilixadencel plus sunitinib show promise for untreated metastatic kidney cancer
A phase 2 clinical trial with a new treatment called [...]
